Medical principles and practice : international journal of the Kuwait University, Health Science Centre
-
Meta Analysis
Efficacy and Safety of Ac-225 PSMA Radio Ligand Therapy in Metastatic Prostate Cancer. A Systematic Review and Metanalysis.
Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225, being an alpha emitter, is expected to have higher efficacy and fewer side effects compared to the beta-emitters such as Lutetium-177. We have performed a meta-analysis to assess the therapeutic responses, survival effects, and significant side effects of Ac-225 PSMA RLT in patients with mCRPC. ⋯ Ac-PSMA RLT is a safe and potentially effective treatment option for patients with mCRPC.